Has Scott Shurmur, MD received payments from drug or device companies?

Yes. Drug and device makers reported $8,813 in general payments to Scott Shurmur, MD across 104 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Scott Shurmur, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Scott Shurmur, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Scott Shurmur, MD

Interventional Cardiology · Lubbock, TXNPI 1447201355

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (43.1%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Sanofi-aventis U.S. LLC at 40.7% of the total. Reporting peaked in 2019 at $6,906 and has fallen 85.1% since, to $1,026 in 2025. That places this record below the midpoint for interventional cardiology clinicians in TX, where the typical reported total is $9,094.

$8,813in general payments, 2019–2025

Across 104 payments — averaging $84.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Sanofi-aventis U.S. LLC$4K
Abbott$2K
Regeneron Healthcare Solutions, Inc.$1K
Medicure Pharma Inc.$500
AstraZeneca$459
Medtronic$433
plus $1K from 13 others

$11,046in research payments, 2019–2025

Across 2 payments — averaging $5522.92 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

AstraZeneca$9K
Amgen$2K

What the payments were for

Consulting fees$3,80043%
Travel & lodging$1,08612%
Food & beverage$3,72442%
Education$2032%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Sanofi-aventis U.S. LLC	9	$3,586
Abbott	16	$1,592
Regeneron Healthcare Solutions, Inc.	24	$1,219
Medicure Pharma Inc.	1	$500
AstraZeneca(2 entities)	23	$459
Medtronic	9	$433
Amgen	2	$177
Edwards Lifesciences	5	$135
Heartflow, Inc.	1	$120
Akcea Therapeutics, Inc.	2	$119
Abiomed	2	$102
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)	2	$100
Regeneron	1	$99
Kowa Pharmaceuticals America, Inc.	1	$59
Philips North America LLC	2	$34
Cardiovascular Systems Inc.	1	$34
Stryker	1	$23
Esperion Therapeutics, Inc.	1	$19
Travere Therapeutics, Inc.	1	$1

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,813 in reported general payments places this provider in the 45th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas →

Medicare billing

Part B allowed, 2024

$36,870

Medicare patients

684

Services billed

1,158

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	40	$50,256
Praluent PenAlirocumab	36	$17,928
XareltoRivaroxaban	16	$11,765
Repatha SureclickEvolocumab	13	$6,719
Nebivolol Hcl	108	$5,248
Rosuvastatin Calcium	193	$2,778
Ezetimibe	52	$1,122
Lisinopril	102	$773
Amlodipine Besylate	94	$729
Carvedilol	74	$726
Ramipril	53	$688
Amiodarone Hcl	16	$640
Losartan Potassium	52	$559
Atorvastatin Calcium	80	$500
Pravastatin Sodium	34	$484

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Lubbock

Mohammad AnsariLubbock$228K
Juan KurdiLubbock$193K
Juan GranadaHouston$4.1M
Vamsi KrishnaKyle$2M
Jeffrey CarrTyler$1.9M
John IsaacHouston$1.8M
Robert ChiltonSan Antonio$1.3M
Sameh SayfoPlano$1M
Srinivasa PotluriPlano$781K
Karim Al-AziziPlano$734K

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →